Jasper Therapeutics: approves reverse split authorization and share increase

What happened The filing reports that at a special meeting of stockholders on Sep 30, 2026, Jasper Therapeutics, Inc. stockholders approved three proposals, including an amendment to permit the board to effect a reverse stock split at a ratio between 1-for-15 and 1-for-35 on or before Dec 31, 2026, and an amendment to increase the number of authorized shares of common stock. A total of 21,747,865 shares of Common Stock, or approximately 65.36% of 33,274,561 shares issued and outstanding as of Aug 10, 2026, were represented virtually or by proxy.

Key details

• Reverse stock split authorization approved: board may effect a reverse stock split at a ratio within the range of 1-for-15 to 1-for-35, without reducing the authorized number of shares and without further stockholder approval. Vote: For 21,088,353; Against 567,692; Abstentions 91,820; Broker non-votes none.
• Authorized share increase approved: amendment to increase authorized shares of Common Stock from 490,000,000 shares to 675,000,000 shares, to be effected in the sole discretion of the board. Vote: For 20,722,644; Against 903,655; Abstentions 121,566.
• Adjournment proposal approved: to adjourn the meeting if necessary to solicit additional proxies. Vote: For 20,938,915; Against 528,123; Abstentions 280,827.

Why it may matter The report is Item 5.07, submission of matters to a vote of security holders, and covers the stockholder votes approving (1) authorization for the board to effect a reverse stock split within a specified ratio range and (2) an increase in the number of authorized common shares, plus a procedural adjournment proposal. The filing does not show why the company acted.